PL2872145T3 - Połączone benzazepiny w leczeniu zespołu tourette’a - Google Patents

Połączone benzazepiny w leczeniu zespołu tourette’a

Info

Publication number
PL2872145T3
PL2872145T3 PL13815988T PL13815988T PL2872145T3 PL 2872145 T3 PL2872145 T3 PL 2872145T3 PL 13815988 T PL13815988 T PL 13815988T PL 13815988 T PL13815988 T PL 13815988T PL 2872145 T3 PL2872145 T3 PL 2872145T3
Authority
PL
Poland
Prior art keywords
tourette
syndrome
treatment
fused benzazepines
benzazepines
Prior art date
Application number
PL13815988T
Other languages
English (en)
Inventor
Richard E. Chipkin
Rudolf KWAN
Original Assignee
Emalex Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emalex Biosciences, Inc. filed Critical Emalex Biosciences, Inc.
Publication of PL2872145T3 publication Critical patent/PL2872145T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL13815988T 2012-07-12 2013-07-12 Połączone benzazepiny w leczeniu zespołu tourette’a PL2872145T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261671044P 2012-07-12 2012-07-12
EP13815988.4A EP2872145B8 (en) 2012-07-12 2013-07-12 Fused benzazepines for treatment of tourette's syndrome
PCT/US2013/050337 WO2014012034A1 (en) 2012-07-12 2013-07-12 Fused benzazepines for treatment of tourette's syndrome

Publications (1)

Publication Number Publication Date
PL2872145T3 true PL2872145T3 (pl) 2022-06-20

Family

ID=49916578

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13815988T PL2872145T3 (pl) 2012-07-12 2013-07-12 Połączone benzazepiny w leczeniu zespołu tourette’a
PL21170063.8T PL3919060T3 (pl) 2012-07-12 2013-07-12 Ekopipam do leczenia zespołu tourette'a

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21170063.8T PL3919060T3 (pl) 2012-07-12 2013-07-12 Ekopipam do leczenia zespołu tourette'a

Country Status (21)

Country Link
US (2) US11298361B2 (pl)
EP (3) EP2872145B8 (pl)
JP (1) JP6181754B2 (pl)
KR (1) KR20150029713A (pl)
CN (1) CN104540510A (pl)
AU (1) AU2013289922B2 (pl)
CA (1) CA2879020C (pl)
CY (1) CY1125221T1 (pl)
DK (2) DK2872145T3 (pl)
ES (2) ES3041320T3 (pl)
FI (1) FI3919060T3 (pl)
HR (2) HRP20251123T1 (pl)
HU (2) HUE072922T2 (pl)
IL (4) IL292725A (pl)
LT (2) LT3919060T (pl)
PL (2) PL2872145T3 (pl)
PT (2) PT3919060T (pl)
RS (2) RS67203B1 (pl)
SI (2) SI3919060T1 (pl)
SM (2) SMT202200234T1 (pl)
WO (1) WO2014012034A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3057595T (lt) 2013-10-18 2020-08-10 Emalex Biosciences, Inc. Sintezuoti benzazepinai, skirti mikčiojimui gydyti
MX2021003302A (es) 2018-09-20 2021-05-13 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
CN121891333A (zh) * 2020-06-05 2026-04-21 诺埃玛制药公司 用于治疗杜尔雷斯综合征的磷酸二酯酶10抑制剂的用途
US12594281B2 (en) 2024-03-15 2026-04-07 Emalex Biosciences, Inc. Pharmaceutical dosage forms and methods of use
WO2025194153A1 (en) * 2024-03-15 2025-09-18 Emalex Biosciences, Inc. Pharmaceutical dosage forms and methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477378A (en) 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4973586A (en) 1986-01-16 1990-11-27 Schering Corporation Fused benzazepines, compositions of, and medical use thereof
US5302716A (en) 1986-01-16 1994-04-12 Schering Corporation Fused benzazepines
BE1005064A4 (nl) 1991-07-03 1993-04-06 Asm Fico Tooling Buiginrichting.
GB9127306D0 (en) 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
WO1995025102A1 (en) 1994-03-16 1995-09-21 Novo Nordisk A/S Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds
US5607967A (en) * 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
KR20010031470A (ko) 1997-10-28 2001-04-16 둘락 노먼 씨. 포유동물의 갈망을 감소시키는 방법
BR9908392A (pt) * 1998-03-02 2000-10-31 Schering Corp Uso de antagonistas de d1/d5 para o tratamento de distúrbios obsessivos compulsivos, distúrbios somatofórmicos, distúrbios dissociativos, distúrbios de alimentação, distúrbios de controle de impulsos e autismo
US6132724A (en) 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
WO2003039468A2 (en) 2001-11-06 2003-05-15 Haracz John L Antimnemonic therapy for hypermemory syndromes
US8518933B2 (en) 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
WO2011057199A1 (en) * 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2012033874A1 (en) * 2010-09-10 2012-03-15 Chipkin Richard E Method of treating compulsive self-injurious behaviors
LT3057595T (lt) 2013-10-18 2020-08-10 Emalex Biosciences, Inc. Sintezuoti benzazepinai, skirti mikčiojimui gydyti

Also Published As

Publication number Publication date
RS63266B1 (sr) 2022-06-30
IL236403A0 (en) 2015-02-26
SMT202200234T1 (it) 2022-07-21
LT3919060T (lt) 2025-10-10
PT2872145T (pt) 2022-05-26
EP2872145B1 (en) 2022-03-09
US20210275540A1 (en) 2021-09-09
CA2879020C (en) 2021-02-09
KR20150029713A (ko) 2015-03-18
EP2872145A1 (en) 2015-05-20
ES2914043T3 (es) 2022-06-07
PL3919060T3 (pl) 2025-10-20
HUE058696T2 (hu) 2022-09-28
RS67203B1 (sr) 2025-10-31
WO2014012034A1 (en) 2014-01-16
EP2872145A4 (en) 2015-12-02
SI2872145T1 (sl) 2022-07-29
AU2013289922A1 (en) 2015-01-29
AU2013289922B2 (en) 2016-12-15
LT2872145T (lt) 2022-06-27
PT3919060T (pt) 2025-09-25
DK3919060T3 (da) 2025-09-15
EP4616915A3 (en) 2025-12-17
EP3919060B1 (en) 2025-06-18
US11298361B2 (en) 2022-04-12
EP2872145B8 (en) 2022-04-13
HK1209336A1 (zh) 2016-04-01
CY1125221T1 (el) 2025-03-28
DK2872145T3 (da) 2022-06-13
JP2015522082A (ja) 2015-08-03
JP6181754B2 (ja) 2017-08-16
IL292725A (en) 2022-07-01
EP3919060A1 (en) 2021-12-08
CA2879020A1 (en) 2014-01-16
SMT202500353T1 (it) 2025-11-10
FI3919060T3 (fi) 2025-09-15
IL300144A (en) 2023-03-01
ES3041320T3 (en) 2025-11-11
HUE072922T2 (hu) 2025-12-28
SI3919060T1 (sl) 2025-11-28
CN104540510A (zh) 2015-04-22
EP4616915A2 (en) 2025-09-17
IL284615A (en) 2021-08-31
HRP20251123T1 (hr) 2025-11-21
HRP20220701T1 (hr) 2022-07-08
US20150164911A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
HRP20200245T1 (hr) Postupci za pripravu (s)-1-(3-etoksi-4metoksifenil)-2-metansulfoniletilamina
IL237275A0 (en) Compounds for the treatment of paramoxovirus viral infections
ZA201403795B (en) Formulations for the treatment of diabetes
ZA201405820B (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
IL284615A (en) Benzazepines are combined for the treatment of Tourette syndrome
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
SG11201504201RA (en) Purification of x-ray contrast agents
ZA201400488B (en) Compounds for the treatment of cancers associated with human papillomavirus
IL232294B (en) Preparations for the treatment of diabetes
GB201215527D0 (en) Compounds for the treatment of muscular dystrophy
GB201206767D0 (en) Treatment of optical aberration
AP2015008270A0 (en) Preparation for the treatment of tuberculosis
PL399423A1 (pl) Sposób wytwarzania 2'-hydroksydihydrochalkonu
PL399422A1 (pl) Sposób wytwarzania 2',4,4',6'-tetrahydroksydihydrochalkonu
PL398695A1 (pl) Sposób wytwarzania 2'-hydroksydihydrochalkonu